Novo Nordisk Stock Rises as UBS Upgrades Ozempic Maker, Calls Sell-Off 'Overdone'

Key TakeawaysNovo Nordisk shares rose Wednesday on the company's home market in Denmark and in the U.S. after UBS analysts upgraded the stock.The analysts upgraded the Ozempic obesity drugmaker to a "buy," but lowered their price target as Novo Nordisk shares are now roughly 40% below their mid-2024 highs.UBS analysts also lowered their sales projections, saying expiring patents and disappointing trial results of future weight-loss drugs could negatively affect sales from 2031 onward. Novo Nordisk's (NVO) U ...